OTCMKTS:RSPI

RespireRx Pharmaceuticals Competitors

$0.04

0.00 (0.00 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.03

Now: $0.04▼

$0.05

50-Day Range

$0.03

MA: $0.05▼

$0.07

52-Week Range

$0.01

Now: $0.04▼

$0.26

Volume724,392 shs

Average Volume1.51 million shs

Market Capitalization$2.82 million

P/E RatioN/A

Dividend YieldN/A

Beta0.43

RespireRx Pharmaceuticals (OTCMKTS:RSPI) Vs. PKPH, WHCA, ACUR, GBIM, ULUR, and NXEN

Should you be buying RSPI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to RespireRx Pharmaceuticals, including Peak Pharmaceuticals (PKPH), Williston (WHCA), Acura Pharmaceuticals (ACUR), GlobeImmune (GBIM), ULURU (ULUR), and Nexien BioPharma (NXEN).

RespireRx Pharmaceuticals vs. Peak Pharmaceuticals Stock

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares RespireRx Pharmaceuticals and Peak Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RespireRx Pharmaceuticals	N/A	N/A	-3,387.16%
Peak Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for RespireRx Pharmaceuticals and Peak Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RespireRx Pharmaceuticals	0	0	0	0	N/A
Peak Pharmaceuticals	0	0	0	0	N/A

Volatility & Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Valuation & Earnings

This table compares RespireRx Pharmaceuticals and Peak Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RespireRx Pharmaceuticals	N/A	N/A	$-2,120,000.00	N/A	N/A
Peak Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Summary

Peak Pharmaceuticals beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

RespireRx Pharmaceuticals vs. Williston Stock

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Williston (OTCMKTS:WHCA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares RespireRx Pharmaceuticals and Williston's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RespireRx Pharmaceuticals	N/A	N/A	-3,387.16%
Williston	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for RespireRx Pharmaceuticals and Williston, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RespireRx Pharmaceuticals	0	0	0	0	N/A
Williston	0	0	0	0	N/A

Volatility & Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Williston has a beta of -1.09, meaning that its stock price is 209% less volatile than the S&P 500.

Valuation & Earnings

This table compares RespireRx Pharmaceuticals and Williston's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RespireRx Pharmaceuticals	N/A	N/A	$-2,120,000.00	N/A	N/A
Williston	N/A	N/A	N/A	N/A	N/A

RespireRx Pharmaceuticals vs. Acura Pharmaceuticals Stock

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Acura Pharmaceuticals (OTCMKTS:ACUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares RespireRx Pharmaceuticals and Acura Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RespireRx Pharmaceuticals	N/A	N/A	-3,387.16%
Acura Pharmaceuticals	-19.89%	-1.36%	-34.83%

Volatility and Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for RespireRx Pharmaceuticals and Acura Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RespireRx Pharmaceuticals	0	0	0	0	N/A
Acura Pharmaceuticals	0	0	0	0	N/A

Earnings and Valuation

This table compares RespireRx Pharmaceuticals and Acura Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RespireRx Pharmaceuticals	N/A	N/A	$-2,120,000.00	N/A	N/A
Acura Pharmaceuticals	$2.66 million	3.49	N/A	N/A	N/A

Acura Pharmaceuticals has higher revenue and earnings than RespireRx Pharmaceuticals.

RespireRx Pharmaceuticals vs. GlobeImmune Stock

GlobeImmune (OTCMKTS:GBIM) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares GlobeImmune and RespireRx Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlobeImmune	N/A	N/A	N/A
RespireRx Pharmaceuticals	N/A	N/A	-3,387.16%

Valuation & Earnings

This table compares GlobeImmune and RespireRx Pharmaceuticals' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlobeImmune	N/A	N/A	N/A	N/A	N/A
RespireRx Pharmaceuticals	N/A	N/A	$-2,120,000.00	N/A	N/A

Analyst Ratings

This is a summary of current ratings and price targets for GlobeImmune and RespireRx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlobeImmune	0	0	0	0	N/A
RespireRx Pharmaceuticals	0	0	0	0	N/A

Volatility and Risk

GlobeImmune has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Summary

GlobeImmune beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

RespireRx Pharmaceuticals vs. ULURU Stock

ULURU (OTCMKTS:ULUR) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for ULURU and RespireRx Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ULURU	0	0	0	0	N/A
RespireRx Pharmaceuticals	0	0	0	0	N/A

Profitability

This table compares ULURU and RespireRx Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ULURU	N/A	N/A	N/A
RespireRx Pharmaceuticals	N/A	N/A	-3,387.16%

Earnings and Valuation

This table compares ULURU and RespireRx Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ULURU	N/A	N/A	N/A	N/A	N/A
RespireRx Pharmaceuticals	N/A	N/A	$-2,120,000.00	N/A	N/A

Volatility & Risk

ULURU has a beta of -2.9, meaning that its share price is 390% less volatile than the S&P 500. Comparatively, RespireRx Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

RespireRx Pharmaceuticals vs. Nexien BioPharma Stock

RespireRx Pharmaceuticals (OTCMKTS:RSPI) and Nexien BioPharma (OTCMKTS:NXEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for RespireRx Pharmaceuticals and Nexien BioPharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RespireRx Pharmaceuticals	0	0	0	0	N/A
Nexien BioPharma	0	0	0	0	N/A

Earnings & Valuation

This table compares RespireRx Pharmaceuticals and Nexien BioPharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RespireRx Pharmaceuticals	N/A	N/A	$-2,120,000.00	N/A	N/A
Nexien BioPharma	N/A	N/A	$-2,670,000.00	N/A	N/A

Profitability

This table compares RespireRx Pharmaceuticals and Nexien BioPharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RespireRx Pharmaceuticals	N/A	N/A	-3,387.16%
Nexien BioPharma	N/A	-16,049.80%	-6,651.95%

Volatility and Risk

RespireRx Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Nexien BioPharma has a beta of -701.47, meaning that its share price is 70,247% less volatile than the S&P 500.

Summary

RespireRx Pharmaceuticals beats Nexien BioPharma on 4 of the 4 factors compared between the two stocks.